Understanding Risk Factors and Elevating Precision Medicine in Lung Cancer

Chinmay Jani, MD, joined CancerNetwork in the studio once again to provide key insights across different hot topics in the thoracic oncology space. He touched upon risk factors for lung cancer beyond smoking based on recent news regarding Pope Leo XIV, how the disease impacts younger populations, and what novel findings suggest about the role that comprehensive molecular testing can play in precision medicine. Jani reviewed the October 2026 news on Pope Leo XIV, in which the Vatican announced that he had undergone a right lower lobectomy to remove a lung nodule confirmed to be lung adenocarcinoma, despite a lack of smoking history. Later in the month, a subsequent oncological evaluation suggested that no further treatment was necessary for him. This development, Jani noted, not only suggests a need to change the historical paradigm and stigma equating lung cancer solely with tobacco use but demonstrates the value of early detection through screening to help prevent the need for systemic therapy beyond surgery. Jani also detailed findings that he and colleagues published in eClinicalMedicine showing the contribution of factors including air pollution and asbestos to lung cancer mortality. He further described research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting examining global and US trends in lung cancer among young adults, especially those who have never smoked. On top of research dedicated to non-tobacco risk factors, research that Jani and colleagues presented at the IASLC 2026 World Conference on Lung Cancer (WCLC) demonstrated that younger patients who have never smoked more frequently have specific, potentially targetable genetic alterations, including mutations and gene fusions. These data underscore the increasingly targeted nature of the treatment landscape for lung cancer, as clinicians have shifted from general chemotherapy to several specific combination and targeted regimens, such as tyrosine kinase inhibitors for ALK- or EGFR-mutated disease. “For the general population, I would like to deliver one message: lung cancer is no [longer] smoking associated or tobacco associated. There are various other risk factors being associated with lung cancer, and beyond that, there are many lung cancers being diagnosed without any of these risk factors,” Jani concluded. “[The] earlier a cancer is diagnosed, the higher the chances of cure, and that's what oncology is working on: to make lung cancer curable in future.” Jani is a medical oncologist at Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine. 00:00 Introduction 00:25 What Pope Leo XIV’s Diagnosis Shows About Early Detection and Intervention 04:15 Exploring How Non-Tobacco Factors Impact Lung Cancer Mortality 08:09 Understanding Global and US Trends in Lung Cancer Among Younger Adults 12:26 Leveraging Targetable Alterations to Expand Precision Medicine 17:39 Combatting Stigmatization Surrounding Screening and Diagnosis 20:16 The Next Big Research Questions in Thoracic Oncology 23:20 Conclusion #NSCLC #lcsm #UMiami #UniversityofMiami #ASCO #WCLC #pope Don't forget to check us out on: YouTube:    / @cancernetwork   X/Twitter: https://x.com/cancernetwrk?lang=en LinkedIn: https://www.linkedin.com/company/canc... Facebook:   / cancer-network-100059801696024   Instagram:   / cancernetwrk